Although the benefit seen in the CAVE study needs Phase III confirmation, the analysis showed that plasma ctDNA testing may help identify best responders.
An international team saw an overall survival benefit when using BRAF, MEK, and EGFR inhibitors together in previously treated, BRAF-mutated metastatic colorectal cancer patients.
The results confirmed that circulating mutations can be reliably detected and changed during treatment, and showed that they could be a valuable prognostic biomarker.
Results from a recent study clarify some conflicting prior determinations, and provide a new rationale to further explore the FCGR2A biomarker in prospective trials.